Skip to main content

Table 5 Multiple regression final models for UAldo:C dependent variables in total population, Healthy + Stage B1 group and stage C group

From: Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease

  Goodness of fit Variables in the model
  R squared   Coefficient Significance
Total population (a) 0.263 (constant) −0.148 0.881
LA/Ao 1.204 0.013*
Sex (female vs male) 1.838 0.003*
Chihuahua (YES vs NO) 3.615 < 0.001*
Healthy + Stage B1 (b) 0.444 (constant) −2.537 0.101
Sex (female vs male) 1.958 0,014*
UP/UC 4.903 0,052
Chihuahua (YES vs NO) 4.323 < 0.001*
UREA mg/dL 0.089 0.018*
Stage C
(c)
0.145 (constant) 2.395 0.003
Furosemide dose (mg/kg/day) 0.336 0.024
  1. LA/Ao: left atrium-to-aortic root ratio; sex: female = 1, male = 0; Chihuahua: YES = 1, NO = 0; UP/UC Urinary protein-to-creatinine ratio, UREA Serum urea
  2. (a) Backward method step 0 predictors: body weight (kg), age (years), sex (female = 1 vs male = 0), Chihuahua (YES = 1 vs NO = 0), UREA mg/dL, UP/UC, LA/Ao, LVEDDn, E peak velocity m/s, spironolactone (YES = 1 vs NO = 0), pimobendan (YES = 1 vs NO = 0), furosemide (YES = 1 vs NO = 0), ACEI (YES = 1 vs NO = 0)
  3. (b) Backward method step 0 predictors: body weight (kg), age (years), sex (female = 1 vs male = 0), Chihuahua (YES = 1 vs NO = 0), UREA mg/dL, UP/UC, LA/Ao, LVEDDn, E peak velocity m/s, STAGE (Healthy = 0, stage B1 = 1)
  4. (c) Backward method step 0 predictors: body weight (kg), age (years), sex (female = 1 vs male = 0), Chihuahua (YES = 1 vs NO = 0), UREA mg/dL, UP/UC, LA/Ao, LVEDDn, E peak velocity m/s, spironolactone (YES = 1 vs NO = 0), furosemide dose (mg/kg/day), furosemide duration (days), ACEI dose (mg/kg/day), ACEI duration (days)
  5. * = significant (P value < 0.05)